[144] Nurix Therapeutics, Inc. Common stock SEC Filing

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (NRIX) has filed a Form 144 disclosing that shareholder Johannes Van Houte plans to sell 5,402 common shares through Morgan Stanley Smith Barney, with an approximate market value of $60,826.52. The transaction is expected on or about 01 Aug 2025 on the NASDAQ. With 76,449,355 shares outstanding, the proposed sale equals roughly 0.007 % of the company’s equity.

The notice also lists two prior sales in the last three months: 4,304 shares on 30 Jul 2025 for $51,695.34 and 6,198 shares on 02 May 2025 for $70,242.55—together totaling 10,502 shares and $121,938. These shares, like the new lot, originated from restricted stock units acquired on 30 Jul 2025. The filer attests to possessing no undisclosed material adverse information and may be trading under a Rule 10b5-1 plan, indicating procedural compliance rather than a sudden shift in outlook.

Positive

• Sale size is immaterial—just 0.007 % of shares outstanding, limiting dilution or market impact.
• Rule 144 and possible 10b5-1 plan indicate transparent, pre-arranged compliance, reducing risk of opportunistic insider trading.

Negative

• Continued insider selling: 10,502 shares already sold in past three months, which could be perceived negatively by some investors.

Insights

Securities Analyst

TL;DR: Small insider sale (~$61k) under Rule 144; immaterial to float, neutral fundamental impact.

The filing reveals a planned disposition of 5,402 NRIX shares worth about $61k—just 0.007 % of the 76.4 M shares outstanding. Even combined with the 10,502 shares already sold this quarter, insider selling remains de-minimis, suggesting routine liquidity or pre-arranged 10b5-1 activity rather than a bearish signal. No earnings data or strategic disclosures accompany the form, so fundamentals remain unchanged. For investors, the event is non-impactful to valuation but may be tracked for sentiment trends.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5402	60826.52	76449355	08/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/30/2025	Restricted Stock Units	Issuer			5402	07/30/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JOHANNES VAN HOUTE 1700 Owens Street, Suite 205 San Francisco CA 94158	Common	07/30/2025	4304	51695.34
10b5-1 Sales for JOHANNES VAN HOUTE 1700 Owens Street, Suite 205 San Francisco CA 94158	Common	05/02/2025	6198	70242.55

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many NRIX shares are being sold according to the Form 144?

The filing covers 5,402 common shares of Nurix Therapeutics.

What is the estimated value of the NRIX shares to be sold?

The shares have an aggregate market value of $60,826.52.

When is the planned sale date for the NRIX shares?

The approximate sale date listed is August 1, 2025.

How many NRIX shares has the filer sold in the last three months?

The filer previously sold 10,502 shares for total proceeds of about $121,938.

What percentage of outstanding NRIX shares does the new sale represent?

Approximately 0.007 % of the 76,449,355 shares outstanding.